{"id":90411,"date":"2024-01-16T14:03:42","date_gmt":"2024-01-16T19:03:42","guid":{"rendered":"https:\/\/newsroom.carleton.ca\/?p=90411"},"modified":"2025-08-19T09:36:15","modified_gmt":"2025-08-19T13:36:15","slug":"virica-expands-bioprocessing-capabilities-with-carleton-university-partnership","status":"publish","type":"post","link":"https:\/\/carleton.ca\/news\/2024\/virica-expands-bioprocessing-capabilities-with-carleton-university-partnership\/","title":{"rendered":"Virica Expands Bioprocessing Capabilities with Carleton University Partnership"},"content":{"rendered":"\n<section class=\"w-screen px-6 cu-section cu-section--white ml-offset-center md:px-8 lg:px-14\">\n    <div class=\"space-y-6 cu-max-w-child-5xl  md:space-y-10 cu-prose-first-last\">\n\n            <div class=\"cu-textmedia flex flex-col lg:flex-row mx-auto gap-6 md:gap-10 my-6 md:my-12 first:mt-0 max-w-5xl\">\n        <div class=\"justify-start cu-textmedia-content cu-prose-first-last\" style=\"flex: 0 0 100%;\">\n            <header class=\"font-light prose-xl cu-pageheader md:prose-2xl cu-component-updated cu-prose-first-last\">\n                                    <h1 class=\"cu-prose-first-last font-semibold !mt-2 mb-4 md:mb-6 relative after:absolute after:h-px after:bottom-0 after:bg-cu-red after:left-px text-3xl md:text-4xl lg:text-5xl lg:leading-[3.5rem] pb-5 after:w-10 text-cu-black-700 not-prose\">\n                        Virica Expands Bioprocessing Capabilities with Carleton University Partnership\n                    <\/h1>\n                \n                                \n                            <\/header>\n\n                    <\/div>\n\n            <\/div>\n\n    <\/div>\n<\/section>\n\n<p>Virica Biotech Inc. (\u201cVirica\u201d), a leading developer of cell enhancers for scaling of viral vector as well as cell and gene therapy manufacturing will expand its bioprocessing services through a partnership with Carleton University. Slated to open this spring, Virica\u2019s new facility at the university multiplies the Company\u2019s capacity to provide high throughput virology services for customers looking to optimize production of their cell and gene therapies.<\/p>\n\n\n\n<p>\u201cCarleton\u2019s new Health Sciences Building provides us with greater access to modern infrastructure and analytical expertise\u201d said Jean Simon Diallo, Ph.D., CEO of Virica Biotech. \u201cTheir state-of-the-art analytical research facilities and world-class researchers across multiple disciplines open the door to exciting opportunities for partnering with Carleton University as we continue to invest to meet customer demand.\u201d<\/p>\n\n\n\n<p>\u201cWe are very pleased to welcome Virica Biotech to the Carleton campus,\u201d said Rafik Goubran, Ph.D., Vice-President (Research and International) and Chancellor\u2019s&nbsp;Professor, Carleton University. \u201cThis multi-year, multi-million-dollar research and infrastructure partnership will help drive innovation and talent development in the Ottawa region for the creation and manufacturing of advanced therapies.\u201d<\/p>\n\n\n\n<p>This partnership expands on Carleton\u2019s history of supporting Ottawa biotechnology companies. The new open concept facility will include high throughput equipment to accelerate Virica\u2019s bioprocess development and optimizations. In addition to expanded modern infrastructure, this new location enables the development and recruitment of world-class talent with experiential learning and training opportunities for Carleton students. Through this partnership, Carleton will coordinate the establishment of a scholarship fund designed to empower graduate students from traditionally underrepresented groups in science.<\/p>\n\n\n\n<p><strong>About Virica Biotech<\/strong>.<\/p>\n\n\n\n<p>Virica develops cell enhancers for viral vectors that improve the yield and quality of vaccines and cell and gene therapies, allowing developers to economically deploy their products at scale. Virica\u2019s Viral Sensitizer (VSE\u2122) platform reduces production inefficiencies caused by anti-viral defenses in manufacturing cells. Purpose formulated VSE combinations substantially increase manufacturing yields and reduce the cost of goods for a range of life-changing products, including vaccines, gene therapies, and cell therapies. viricabiotech.com<\/p>\n\n\n\n<p><strong>About Carleton University<\/strong><\/p>\n\n\n\n<p>Carleton University is a dynamic, research-intensive institution that engages in partnerships to address the world\u2019s most pressing challenges. The university\u2019s corporate collaborations bring together world-class companies, researchers and a new generation of talent with over 30,000 students to deliver innovations and results that are driving a more prosperous, sustainable future.<\/p>\n\n\n\n<p><strong>Media contact <\/strong><\/p>\n\n\n\n<p>Virica Biotech: Jennifer Cameron; <a href=\"mailto:communications@viricabiotech.com\">communications@viricabiotech.com<\/a>; 1-902-209-4704Carleton University: Steven Reid (he\/him), Media Relations Officer; <a href=\"mailto:Steven.Reid3@carleton.ca\">Steven.Reid3@carleton.ca<\/a>; 613-265-6613<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Virica Biotech Inc. (\u201cVirica\u201d), a leading developer of cell enhancers for scaling of viral vector as well as cell and gene therapy manufacturing will expand its bioprocessing services through a partnership with Carleton University. Slated to open this spring, Virica\u2019s new facility at the university multiplies the Company\u2019s capacity to provide high throughput virology services [&hellip;]<\/p>\n","protected":false},"author":410,"featured_media":90412,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[1],"tags":[104,162,139,91],"class_list":["post-90411","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news-releases","tag-science","tag-health-sciences","tag-partnerships","tag-research"],"acf":{"cu_post_thumbnail":false},"_links":{"self":[{"href":"https:\/\/carleton.ca\/news\/wp-json\/wp\/v2\/posts\/90411","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/carleton.ca\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/carleton.ca\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/carleton.ca\/news\/wp-json\/wp\/v2\/users\/410"}],"replies":[{"embeddable":true,"href":"https:\/\/carleton.ca\/news\/wp-json\/wp\/v2\/comments?post=90411"}],"version-history":[{"count":1,"href":"https:\/\/carleton.ca\/news\/wp-json\/wp\/v2\/posts\/90411\/revisions"}],"predecessor-version":[{"id":90414,"href":"https:\/\/carleton.ca\/news\/wp-json\/wp\/v2\/posts\/90411\/revisions\/90414"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/carleton.ca\/news\/wp-json\/wp\/v2\/media\/90412"}],"wp:attachment":[{"href":"https:\/\/carleton.ca\/news\/wp-json\/wp\/v2\/media?parent=90411"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/carleton.ca\/news\/wp-json\/wp\/v2\/categories?post=90411"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/carleton.ca\/news\/wp-json\/wp\/v2\/tags?post=90411"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}